CION Ameerpet
Mantle cell lymphoma is an uncommon B-cell non-Hodgkin lymphoma with its own molecular fingerprint. This guide explains what it is, how it is diagnosed, what shapes the prognosis, and how CION's haematology team plans and coordinates care.
Mantle cell lymphoma (MCL) is an uncommon type of B-cell non-Hodgkin lymphoma. It develops from B lymphocytes in the mantle zone — the outer rim of cells surrounding a lymph node follicle, which is how it got its name. It accounts for only a small fraction of all lymphomas and is more common in older adults and in men.
What defines MCL is a molecular fingerprint: a swap of genetic material between chromosomes 11 and 14, which switches on a protein called cyclin D1. The pathologist looks for cyclin D1 (and often the marker SOX11) on the biopsy to confirm the diagnosis. MCL usually behaves as a moderately aggressive lymphoma, though a minority of people have a genuinely slow-growing form. It also tends to be widespread when found — commonly involving lymph nodes, the spleen, bone marrow, blood and sometimes the digestive tract.
This guide explains the key symptoms, how MCL is diagnosed, what drives the mantle cell lymphoma prognosis, and the MCL treatment options. For the wider picture, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
Almost all mantle cell lymphomas carry a translocation between chromosomes 11 and 14 — written t(11;14) — which drives over-expression of the cyclin D1 protein. Finding cyclin D1 on the biopsy is the key that confirms the diagnosis and separates MCL from other slow-growing B-cell lymphomas that can look similar under the microscope. (Source: WHO classification of lymphoid tumours, as referenced in NCCN and ESMO mantle cell lymphoma guidelines.)
MCL sits in a tricky middle ground — often aggressive, yet with a slow-growing minority. Getting the subtype and markers exactly right is what makes a plan reliable.
Cyclin D1, SOX11, Ki-67 and the t(11;14) change are confirmed on your biopsy so MCL is not mistaken for small lymphocytic lymphoma or another B-cell subtype — the difference changes the plan.
Chemotherapy, anti-CD20 monoclonal antibody (immunotherapy), targeted B-cell therapy, radiation (IMRT), biopsy and bone-marrow exams are all delivered directly by CION in Hyderabad.
When a stem-cell transplant or CAR-T cell therapy is the right step, CION coordinates it through accredited partner facilities — with your own team managing the pathway end to end.
Every case is reviewed by a multidisciplinary tumour board, and we offer a free written second opinion — especially valuable before starting treatment for an uncommon lymphoma like MCL.
Because MCL is often widespread at diagnosis, symptoms can involve several parts of the body. The most common warning signs include:
These signs overlap with many ordinary conditions, so they are not proof of lymphoma. But a lump or symptom that is new, persistent and unexplained should always be checked. Speak to a CION haematologist if you have these signs or a confirmed MCL diagnosis.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received an MCL diagnosis, want to understand what your Ki-67 and TP53 results mean, or need a second opinion before treatment? CION's haematology team is here.
Diagnosing MCL — and pinning down exactly how it is likely to behave — takes a step-by-step pathway. CION delivers the biopsy, bone-marrow exam, molecular testing and review directly, and coordinates imaging.
A biopsy of an affected lymph node or tissue is the cornerstone. A haematopathologist examines it and runs immunohistochemistry for B-cell markers such as CD20, together with cyclin D1 and often SOX11. The underlying chromosome 11;14 change can be confirmed by a FISH test. This is what separates MCL from look-alike lymphomas.
A CT or PET-CT scan maps how far the disease has spread, and a bone-marrow examination checks for marrow and blood involvement, which is common in MCL. An assessment of the digestive tract may be added, since the stomach and bowel can be involved even without symptoms.
Two things guide the outlook: the Ki-67 proliferation index (how fast the cells are dividing) and TP53 gene status. These, combined with stage and blood tests in the MIPI score, help predict how the lymphoma will behave and which treatment intensity is appropriate. NCCN and ESMO both recommend that this information guides the plan. CION arranges cyclin D1, Ki-67 and TP53 testing as standard.
Not all mantle cell lymphoma behaves the same way. A minority of people have a genuinely slow-growing (indolent) form — often a leukaemic pattern mainly in the blood and spleen, frequently SOX11-negative — that can be safely watched for a time rather than treated straight away. This is why the pace of the disease, the Ki-67 index and TP53 status matter as much as the diagnosis itself when planning MCL treatment. (Source: NCCN and ESMO mantle cell lymphoma guidelines.)
The plan depends on the pace of the disease, your age and fitness, and molecular markers such as Ki-67 and TP53. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set. The main building blocks are:
Most people with active MCL are treated with chemotherapy combined with an anti-CD20 monoclonal antibody, which targets the CD20 marker on the B cells. CION delivers this systemic therapy directly. Specific drug regimens are individualised to your fitness and markers — see our Lymphoma Treatment in Hyderabad page for how regimens are chosen.
Targeted therapy that blocks the B-cell receptor signalling pathway has become an important option in MCL, particularly for disease that comes back. CION's medical oncology team delivers targeted and maintenance therapy directly and uses your marker profile to guide the choice.
Younger, fit patients may be considered for an intensive programme followed by an autologous stem-cell transplant to deepen and lengthen remission. For relapsed or refractory MCL, CAR-T cell therapy is an option. Both transplant and CAR-T are coordinated through accredited partner facilities — not performed in-house — with CION managing the referral and the surrounding care.
A small group with genuinely slow-growing MCL and no troublesome symptoms may be safely monitored with regular reviews and scans, delaying treatment until it is truly needed. Radiation (IMRT) may also be used directly for localised disease or symptom control.
The mantle cell lymphoma prognosis varies widely from person to person, and it has improved substantially with modern therapy. Rather than a single number, the outlook is best understood through the factors that drive it:
Published series report that median survival in MCL is now measured in several years, and some people with slow-growing disease live much longer, while high-Ki-67 or TP53-altered cases are more difficult (per NCCN and ESMO reviews). For context, other lymphomas carry their own figures — Hodgkin lymphoma around 80–90% and DLBCL around 60–70% survival in published series. MCL is generally treatable and can be brought into long remissions, though it is not usually described as curable in the way some lymphomas are. All of these figures vary by individual — your team will explain your own outlook using your specific results.
MCL is one of several B-cell non-Hodgkin lymphomas. Getting the exact subtype right on biopsy is what drives the correct plan — these related pages may help.
The most common aggressive B-cell lymphoma — fast-growing but often curable with chemo-immunotherapy, unlike MCL. See also relapsed or refractory DLBCL.
A slow-growing (indolent) B-cell lymphoma. Read about transformation to aggressive disease and living with an indolent lymphoma.
Another slow-growing subtype; includes MALT lymphoma of the stomach and its H. pylori link.
Can look similar to leukaemic MCL in the blood — cyclin D1 testing is what tells them apart.
Because MCL is uncommon and sits in a middle ground between slow- and fast-growing lymphomas, a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. You can also explore our best lymphoma doctors in Hyderabad and best lymphoma hospital in Hyderabad pages, request your free second opinion, or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if cyclin D1, Ki-67 and TP53 testing has not yet been arranged on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Mantle cell lymphoma (MCL) is an uncommon type of B-cell non-Hodgkin lymphoma. It develops from B lymphocytes in the "mantle zone" — the outer rim of a lymph node follicle. Most cases are driven by a genetic swap between chromosomes 11 and 14 that switches on a protein called cyclin D1, which the pathologist looks for to confirm the diagnosis. MCL usually behaves as a fairly aggressive lymphoma, though a minority follow a slower, more indolent course. It tends to be widespread at diagnosis, often involving lymph nodes, bone marrow, blood and sometimes the digestive tract. For a fuller comparison of subtypes, see the closely related diffuse large B-cell lymphoma (DLBCL).
The most common first sign is painless swelling of lymph nodes in the neck, armpit or groin. Because MCL is often widespread when found, many people also have "B symptoms": unexplained fever, drenching night sweats and weight loss. An enlarged spleen can cause fullness or discomfort on the left side of the tummy, and involvement of the stomach or bowel can cause digestive symptoms. Fatigue is common when the bone marrow is affected. These signs overlap with many harmless conditions, so they are not proof of lymphoma — but a lump or symptom that is new, persistent and unexplained should be checked. If you have concerns, you can book a free consultation with our haematology team.
Diagnosis needs a biopsy of an affected lymph node or tissue, examined by a haematopathologist. The tumour cells are tested by immunohistochemistry for B-cell markers such as CD20 and for cyclin D1, and often for the SOX11 marker; the underlying chromosome 11;14 change can be confirmed by FISH. Staging then maps how far the disease has spread using a CT or PET-CT scan and a bone-marrow examination; blood tests and an assessment of the digestive tract may be added. CION delivers the biopsy, bone-marrow exam, imaging coordination and molecular testing directly, and every case is reviewed by a multidisciplinary tumour board before a plan is set. Explore full pathways on our Lymphoma Treatment in Hyderabad page.
Mantle cell lymphoma prognosis varies widely and depends on the disease stage, the pace of growth, a proliferation marker called Ki-67, TP53 gene status and a score called the MIPI index. Outcomes have improved substantially with modern therapy; published series report median survival now measured in several years, and some people with slow-growing disease live much longer, while cases with high Ki-67 or TP53 changes tend to be more challenging (figures per NCCN and ESMO reviews; outcomes vary by individual). MCL is generally treatable and can be brought into long remissions, but it is not usually described as curable in the way some lymphomas are. Your team will explain your own outlook using your specific test results.
MCL treatment is tailored to the pace of disease, your age and fitness, and molecular markers. Options include chemotherapy, anti-CD20 monoclonal antibody (immunotherapy) and targeted therapy that blocks B-cell signalling — CION delivers these directly. Younger, fit patients may be considered for an intensive programme followed by a stem-cell transplant, and CAR-T cell therapy is an option for relapsed disease; both transplant and CAR-T are coordinated through accredited partner facilities rather than performed in-house. A small group with genuinely slow-growing MCL may be safely watched. Specific drug regimens are individualised — see our Lymphoma Treatment in Hyderabad page or request a plan review.
No — mantle cell lymphoma is a lymphoma, meaning it usually forms in the lymph nodes and lymphatic tissue, whereas leukaemia begins in the bone marrow and blood. However, MCL frequently spills into the blood and bone marrow, so at diagnosis it can look similar to a leukaemia on a blood count. There is also a slow-growing, "leukaemic" form of MCL that mainly involves the blood and spleen with little lymph-node swelling. The confusion is understandable, but the tissue diagnosis — showing mantle-zone B cells with cyclin D1 — defines it as a lymphoma. It sits within the non-Hodgkin lymphoma family of B-cell subtypes.
Mantle cell lymphoma has a distinct fingerprint: mantle-zone B cells carrying the chromosome 11;14 change and over-expressing cyclin D1. This sets it apart from DLBCL, which is a fast-growing large-cell lymphoma, and from follicular lymphoma and marginal zone lymphoma, which are usually slow-growing (indolent). MCL sits awkwardly in between — often behaving aggressively yet, unlike DLBCL, not reliably cured by standard chemo-immunotherapy alone. It also has more overlap with slow-growing lymphomas such as small lymphocytic lymphoma (SLL) when it presents in a leukaemic pattern. Getting the exact subtype right on biopsy is what drives the correct treatment plan.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.